Cumberland Pharmaceuticals, Inc. (CPIX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
4.93-0.04 (-0.80%)
At close: 4:00 PM EDT
People also watch:
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Prev Close4.97
Bid0.00 x
Ask12.00 x 300
Day's Range4.76 - 4.95
52wk Range4.20 - 6.50
1y Target EstN/A
Market Cap79.99M
P/E Ratio (ttm)-493.00
Avg Vol (3m)11,850
Dividend & YieldN/A (N/A)
Earnings DateN/A
Trade prices are not sourced from all markets
  • Capital Cube5 days ago

    ETF’s with exposure to Cumberland Pharmaceuticals, Inc. : October 18, 2016

    Categories: ETFs Yahoo Finance Click here to see latest analysis ETF’s with exposure to Cumberland Pharmaceuticals, Inc. Here are 5 ETF’s with the largest exposure to CPIX-US. Comparing the performance and risk of Cumberland Pharmaceuticals, Inc. with the ETF’s that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • PR Newswire27 days ago

    Cumberland Pharmaceuticals Launches Promotion Of Ethyol® In The United States For Oncology Patient Support

    NASHVILLE, Tenn., Sept. 26, 2016 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (CPIX), announced today that it has launched the U.S. promotion of Ethyol® (amifostine) for Injection, a hospital-based product used to treat oncology patients. Ethyol is an FDA approved cytoprotective drug indicated to reduce the incidence of xerostomia in patients undergoing post-operative radiation treatment for head and neck cancer.  It also reduces the cumulative renal toxicity associated with the repeated administration of cisplatin in patients with advanced ovarian cancer. Cumberland entered into an exclusive agreement with Clinigen Group plc to commercialize Ethyol in the United States earlier this year.

  • PR Newswirelast month

    Cumberland Pharmaceuticals Announces New Program To Develop Portaban™ For Portal Hypertension

    NASHVILLE, Tenn., Sept. 14, 2016 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (CPIX), today announced the initiation of a new Phase II clinical program of Portaban™ for patients with portal hypertension associated with liver disease. The U.S. Food and Drug Administration (FDA) has cleared Cumberland's investigational new drug application (IND) for a multicenter, randomized, double-blind, placebo-controlled Phase II clinical study. Portaban™ is an oral formulation of ifetroban and the fourth development candidate in Cumberland's pipeline.